These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998 [TBL] [Abstract][Full Text] [Related]
10. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Januzzi JL; Chen-Tournoux AA; Moe G Am J Cardiol; 2008 Feb; 101(3A):29-38. PubMed ID: 18243855 [TBL] [Abstract][Full Text] [Related]
11. Use of B-type natriuretic peptide outside of the emergency department. Maeder MT; Mueller C; Pfisterer ME; Buser PT; Brunner-La Rocca HP Int J Cardiol; 2008 Jun; 127(1):5-16. PubMed ID: 18191484 [TBL] [Abstract][Full Text] [Related]
12. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. Miller WL; Burnett JC; Hartman KA; Hodge DO; Giuliani I; Minard F; Larue C; Jaffe AS Clin Chim Acta; 2009 Aug; 406(1-2):119-23. PubMed ID: 19523938 [TBL] [Abstract][Full Text] [Related]
13. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome. Rutten JH; Steyerberg EW; Boomsma F; van Saase JL; Deckers JW; Hoogsteden HC; Lindemans J; van den Meiracker AH Am Heart J; 2008 Jul; 156(1):71-7. PubMed ID: 18585499 [TBL] [Abstract][Full Text] [Related]
16. Natriuretic peptides and their evolving clinical applications. Noveanu M; Potocki M; Mueller C Future Cardiol; 2008 Nov; 4(6):593-8. PubMed ID: 19804353 [TBL] [Abstract][Full Text] [Related]
17. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. Maisel A; Hollander JE; Guss D; McCullough P; Nowak R; Green G; Saltzberg M; Ellison SR; Bhalla MA; Bhalla V; Clopton P; Jesse R; J Am Coll Cardiol; 2004 Sep; 44(6):1328-33. PubMed ID: 15364340 [TBL] [Abstract][Full Text] [Related]
18. Health gains by using natriuretic peptides in diagnosis, prognosis and treatment. Richards M; Troughton R; Lainchbury J; Doughty R; Wright S Scand J Clin Lab Invest Suppl; 2005; 240():129-37. PubMed ID: 16112970 [TBL] [Abstract][Full Text] [Related]
19. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Rudiger A; Gasser S; Fischler M; Hornemann T; von Eckardstein A; Maggiorini M Crit Care Med; 2006 Aug; 34(8):2140-4. PubMed ID: 16763507 [TBL] [Abstract][Full Text] [Related]
20. [Biomarkers in heart failure: BNP and NT-proBNP]. Ho CC; Liu CC Hu Li Za Zhi; 2009 Oct; 56(5):16-22. PubMed ID: 19760573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]